SANGAMO THERAPEUTICS Business Summary

Sangamo Therapeutics, Inc. (SGMO) is a clinical-stage genomic medicine company that generates revenue through strategic licensing agreements, milestone payments, and potential future royalties from its proprietary zinc finger protein (ZFP) technology platform. The company's business model has pivoted toward a "neurology-first" strategy, focusing on epigenetic regulation and gene therapy for central nervous system (CNS) disorders, including chronic neuropathic pain and prion disease. Its primary business segments include its Priority Neurology Pipeline, partnered programs in hemophilia A (with Pfizer) and Huntington’s disease, and wholly owned clinical assets such as isaralgagene civaparvovec for Fabry disease and TX200 for renal transplant rejection. Sangamo competes directly with genomic medicine peers such as CRISPR Therapeutics, Intellia Therapeutics, and Beam Therapeutics; however, it distinguishes itself by utilizing ZFP-mediated epigenetic repression and activation, which allows for precise gene regulation without the double-stranded DNA breaks characteristic of CRISPR-based approaches. The company was founded in 1995 by Edward Lanphier, who served as the long-time CEO and remains a significant individual stakeholder. The current leadership team is headed by CEO Dr. Sandy Macrae, who joined in 2016 following senior executive roles at Takeda and GlaxoSmithKline. Supporting him are Chief Technical Officer Phillip Ramsey, Chief Development Officer Dr. Nathalie Dubois-Stringfellow, and Interim Chief Financial Officer Nikunj Jain. The technical direction is overseen by Dr. Gregory Davis, Head of Research and Technology, a veteran of the company’s ZFP development. Sangamo’s board is chaired by H. Stewart Parker, founder of Targeted Genetics, and includes notable industry figures such as Dr. Karen Smith and James Meyers. The company maintains strategic institutional backing from Biogen, which remains a top shareholder and collaborator, alongside major investment firms like Vanguard and BlackRock.